Penumbra (PEN) Income from Continuing Operations (2014 - 2026)
Penumbra's (PEN) quarterly Income from Continuing Operations came in at 32588000.0 in Q1 2026, down 16.92% year-on-year from 39223000.0 in Q1 2025, and down 31.17% on a QoQ basis from 47343000.0 in Q4 2025.
Penumbra (PEN) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Income from Continuing Operations data on file, last reported at 32588000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 16.92% year-over-year to 32588000.0 in Q1 2026; TTM through Mar 2026 was 171092000.0, a 305.59% increase from a year earlier, with the FY2025 full-year figure at 177687000.0, up 1168.11% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 32588000.0, down from 47343000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for PEN reached as high as 54218000.0 in Q4 2023 and fell as low as 60200000.0 in Q2 2024.
- Historically, Income from Continuing Operations has averaged 18423823.53 across 5 years, with a median of 18936000.0 in 2023.
- Across the five-year window, Income from Continuing Operations jumped 10737.97% in 2023 and slumped 417.91% in 2024, its largest moves.
- Year by year, Income from Continuing Operations stood at 3877000.0 in 2022, then surged by 1298.45% to 54218000.0 in 2023, then plunged by 37.88% to 33682000.0 in 2024, then soared by 40.56% to 47343000.0 in 2025, then slumped by 31.17% to 32588000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 32588000.0 in Q1 2026, 47343000.0 in Q4 2025, and 45851000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 32.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.59 Mn |
| Dec 31, 2025 | 47.34 Mn |
| Sep 30, 2025 | 45.85 Mn |
| Jun 30, 2025 | 45.31 Mn |
| Mar 31, 2025 | 39.22 Mn |
| Dec 31, 2024 | 33.68 Mn |
| Sep 30, 2024 | 29.48 Mn |
| Jun 30, 2024 | -60.20 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Dec 31, 2023 | 54.22 Mn |
| Sep 30, 2023 | 9.21 Mn |
| Jun 30, 2023 | 18.94 Mn |
| Mar 31, 2023 | 8.56 Mn |
| Dec 31, 2022 | 3.88 Mn |
| Sep 30, 2022 | -2.27 Mn |
| Jun 30, 2022 | -3.69 Mn |
| Mar 31, 2022 | 79,000.00 |
| Dec 31, 2021 | -24.63 Mn |
| Sep 30, 2021 | 8.03 Mn |
| Jun 30, 2021 | 8.30 Mn |